174 related articles for article (PubMed ID: 37560306)
1. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.
Tseng CH
Oncotarget; 2017 Mar; 8(12):19057-19064. PubMed ID: 27661113
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients.
Tseng CH
Aging (Albany NY); 2019 May; 11(9):2724-2734. PubMed ID: 31085804
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Tseng CH
BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
[TBL] [Abstract][Full Text] [Related]
5. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
Tseng CH
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439890
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Jan; 8(2):3042-3048. PubMed ID: 27936468
[TBL] [Abstract][Full Text] [Related]
7. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes.
Tseng CH
Ann Med; 2013 Dec; 45(8):539-44. PubMed ID: 24215589
[TBL] [Abstract][Full Text] [Related]
9. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus.
Tseng CH
Sci Rep; 2021 Jun; 11(1):12400. PubMed ID: 34117321
[TBL] [Abstract][Full Text] [Related]
10. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
[TBL] [Abstract][Full Text] [Related]
11. Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Jun; 8(25):41132-41142. PubMed ID: 28456789
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients.
Tseng CH
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242462
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(38):62687-62696. PubMed ID: 27409676
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone is not associated with an increased risk of bladder cancer.
Tseng CH
Cancer Epidemiol; 2013 Aug; 37(4):385-9. PubMed ID: 23619142
[TBL] [Abstract][Full Text] [Related]
15. Metformin use and cervical cancer risk in female patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(37):59548-59555. PubMed ID: 27486978
[TBL] [Abstract][Full Text] [Related]
16. Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
Tseng CH
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680039
[No Abstract] [Full Text] [Related]
17. Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Mar; 8(12):18802-18810. PubMed ID: 27861146
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.
Tseng CH
Aging (Albany NY); 2016 Aug; 8(8):1636-49. PubMed ID: 27587088
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Tseng CH
Int J Chron Obstruct Pulmon Dis; 2022; 17():285-295. PubMed ID: 35177899
[TBL] [Abstract][Full Text] [Related]
20. Metformin reduces risk of varicose veins in patients with type 2 diabetes.
Tseng CH
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3206. PubMed ID: 31322821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
